Shots: Chugai and Sanofi terminate their 2012 licensing agreement, allowing Sanofi to transfer marketing rights of Apleway to Kowa as of Apr 01, 2020 with the anticipated transfer of marketing […]readmore
Tags : Licensing Agreement
Shots: Under the expanded collaboration, Equillium gets an exclusive right to develop and commercialize Biocon’s itolizumab in Australia and New Zealand. In May’2017, Biocon partnered with Equillium to develop a […]readmore
Shots: Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim to get right to utilize Lupin’s LNP3794 […]readmore
Shots: The extended agreement allows Cantargia to create and use additional CHO cell lines engineered utilizing BioWa’s POTELLIGENT technology and to develop and commercialize CAN04 developed via CHO cell lines […]readmore
Shots: Zenith Epigenetics will receive $15M as up front and development milestones, ~$63M commercial milestones and up to 6% royalties on sales in the licensed territories which may reduce to […]readmore
Shots: Eagle to receive royalties increased from 25% to 30% on sales of Bendeka in the US and will keep increasing by 1% until it reaches 32%, on every Oct […]readmore